Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Christian Klein, Candice Jamois & Tina Nielsen. (2021) Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opinion on Biological Therapy 21:2, pages 161-181.
Read now
Read now
J. M. L. Casan, J. Wong, M. J. Northcott & S. Opat. (2018) Anti-CD20 monoclonal antibodies: reviewing a revolution. Human Vaccines & Immunotherapeutics 14:12, pages 2820-2841.
Read now
Read now
Frank Herting, Thomas Friess, Pablo Umaña, Steven Middleton & Christian Klein. (2018) Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. Leukemia & Lymphoma 59:6, pages 1482-1485.
Read now
Read now
Maryam Sarraf Yazdy & Bruce D Cheson. (2017) Impact of obinutuzumab alone and in combination for follicular lymphoma. Blood and Lymphatic Cancer: Targets and Therapy 7, pages 73-83.
Read now
Read now
Othman Al-Sawaf, Kirsten Fischer, Anja Engelke, Natali Pflug, Michael Hallek & Valentin Goede. (2017) Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Design, Development and Therapy 11, pages 295-304.
Read now
Read now
Rabih Said & Apostolia M. Tsimberidou. (2017) Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opinion on Biological Therapy 17:11, pages 1463-1470.
Read now
Read now
Christian Klein, Marina Bacac, Pablo Umana & Günter Fingerle-Rowson. (2017) Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert Opinion on Investigational Drugs 26:10, pages 1145-1162.
Read now
Read now
Barbara Ma & Chaitra Ujjani. (2017) The clinical development of obinutuzumab for the treatment of follicular lymphoma. Cancer Management and Research 9, pages 103-113.
Read now
Read now
Tomoko Yasuhiro, Wako Sawada, Christian Klein, Ryohei Kozaki, Shingo Hotta & Toshio Yoshizawa. (2017) Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. Leukemia & Lymphoma 58:3, pages 699-707.
Read now
Read now
G. Reda, N. Orofino, R. Cassin, M. Sciumè, B. Fattizzo & A. Cortelezzi. (2016) Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations. Expert Opinion on Drug Safety 15:6, pages 865-873.
Read now
Read now
Lukáš Smolej. (2015) Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmacogenomics and Personalized Medicine 8, pages 1-7.
Read now
Read now
Hua-Fei Li, Cong Wu, Ting Chen, Ge Zhang, He Zhao, Chang-Hong Ke & Zheng Xu. (2015) Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity. International Journal of Nanomedicine 10, pages 4783-4796.
Read now
Read now
Sonia Cerquozzi & Carolyn Owen. (2015) Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. Biologics: Targets and Therapy 9, pages 13-22.
Read now
Read now
Karen Seiter & Aleksandra Mamorska-Dyga. (2015) Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clinical Interventions in Aging 10, pages 951-961.
Read now
Read now
Yuzhi Liu, Ling Shu & Jingjing Wu. (2015) Ceramide participates in lysosome-mediated cell death induced by type II anti-CD20 monoclonal antibodies. Leukemia & Lymphoma 56:6, pages 1863-1868.
Read now
Read now
Catherine Rioufol & Gilles Salles. (2014) Obinutuzumab for chronic lymphocytic leukemia. Expert Review of Hematology 7:5, pages 533-543.
Read now
Read now
Tim Illidge, Eleanor J Cheadle, Claire Donaghy & Jamie Honeychurch. (2014) Update on obinutuzumab in the treatment of B-cell malignancies. Expert Opinion on Biological Therapy 14:10, pages 1507-1517.
Read now
Read now
Articles from other publishers (25)
Luigi Rigacci, Roberta Battistini, Sofia Kovalchuk, Valerio Zoli, Benedetta Puccini, Andrea Evangelista, Luca Arcaini, Leonardo Flenghi, Carlo Visco, Michael Mian, Alice Di Rocco, Claudia Peracchio, Manuel Gotti, Maria Chiara Tisi, Francesca Palombi, Samantha Pozzi, Daniela Gioia, Piera Viero & Maurizio Martelli. (2022) Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study). Hematological Oncology 40:4, pages 609-616.
Crossref
Crossref
Yoriko Yamashita-Kashima, Keigo Yorozu, Takaaki Fujimura, Natsumi Kawasaki, Mitsue Kurasawa, Shigeki Yoshiura, Naoki Harada, Osamu Kondoh & Yasushi Yoshimura. (2022) Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors. International Journal of Hematology 115:6, pages 860-872.
Crossref
Crossref
Urszula Karczmarczyk, Agnieszka Sawicka, Piotr Garnuszek, Michał Maurin & Wioletta Wojdowska. (2022)
Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with
90
Y or
177
Lu
. Journal of Medicinal Chemistry 65:9, pages 6419-6430.
Crossref
Crossref
Yoshiki Narimatsu, Christian Büll, Yen-Hsi Chen, Hans H. Wandall, Zhang Yang & Henrik Clausen. (2021) Genetic glycoengineering in mammalian cells. Journal of Biological Chemistry 296, pages 100448.
Crossref
Crossref
Yossra A. Trabik, Eman M. Moenes, Medhat A. Al-Ghobashy, Marianne Nebsen & Miriam F. Ayad. (2020) Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering. Journal of Chromatography B 1159, pages 122359.
Crossref
Crossref
Ida Franiak-Pietryga, Barbara Ziemba, Hanna Sikorska, Magdalena Jander, Wojciech Kuncman, Marian Danilewicz, Dietmar Appelhans, Przemyslaw Lewkowicz, Kinga Ostrowska, Maria Bryszewska & Maciej Borowiec. (2020) Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL. Toxicology and Applied Pharmacology 403, pages 115139.
Crossref
Crossref
Simon Latour, Marion Zanese, Valérie Le Morvan, Anne-Marie Vacher, Nelly Menard, Fontanet Bijou, Francoise Durrieu, Pierre Soubeyran, Ariel Savina, Pierre Vacher & Laurence Bresson-Bepoldin. (2019) Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells. Cancers 11:3, pages 291.
Crossref
Crossref
Marina Bacac, Sara Colombetti, Sylvia Herter, Johannes Sam, Mario Perro, Stanford Chen, Roberta Bianchi, Marine Richard, Anne Schoenle, Valeria Nicolini, Sarah Diggelmann, Florian Limani, Ramona Schlenker, Tamara Hüsser, Wolfgang Richter, Katharine Bray-French, Heather Hinton, Anna Maria Giusti, Anne Freimoser-Grundschober, Laurent Lariviere, Christiane Neumann, Christian Klein & Pablo Umaña. (2018) CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clinical Cancer Research 24:19, pages 4785-4797.
Crossref
Crossref
Christian Klein, Ekkehard Mössner, Marina Bacac, Günter Fingerle-Rowson & Pablo Umaña. 2018. Successful Drug Discovery. Successful Drug Discovery
245
289
.
Estíbaliz Tamayo-Orbegozo, Laura Amo, Marta Riñón, Naiara Nieto, Elena Amutio, Natalia Maruri, Miren Solaun, Arantza Arrieta & Susana Larrucea. (2017) Podocalyxin promotes proliferation and survival in mature B-cell non-Hodgkin lymphoma cells. Oncotarget 8:59, pages 99722-99739.
Crossref
Crossref
Guillaume CartronHervé Watier. (2017) Obinutuzumab: what is there to learn from clinical trials?. Blood 130:5, pages 581-589.
Crossref
Crossref
E J Cheadle, G Lipowska-Bhalla, S J Dovedi, E Fagnano, C Klein, J Honeychurch & T M Illidge. (2016) A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia 31:7, pages 1611-1621.
Crossref
Crossref
Wei Wen Chien, Charlène Niogret, Romain Jugé, Loïc Lionnard, Aurélie Cornut-Thibaut, Jérôme Kucharczak, Ariel Savina, Gilles Salles & Abdel Aouacheria. (2017) Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101. Leukemia Research 55, pages 41-48.
Crossref
Crossref
Sohita Dhillon. (2017) Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma. Targeted Oncology 12:2, pages 255-262.
Crossref
Crossref
Kensei Tobinai, Christian Klein, Naoko Oya & Günter Fingerle-Rowson. (2016) A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Advances in Therapy 34:2, pages 324-356.
Crossref
Crossref
Frank Herting, Sylvia Herter, Thomas Friess, Gunther Muth, Marina Bacac, Jitka Sulcova, Pablo Umana, Markus Dangl & Christian Klein. (2016)
Antitumour activity of the glycoengineered type
II
anti‐
CD
20 antibody obinutuzumab (
GA
101) in combination with the
MDM
2‐selective antagonist idasanutlin (
RG
7388)
. European Journal of Haematology 97:5, pages 461-470.
Crossref
Crossref
Ludovic Gabellier & Guillaume Cartron. (2015) Obinutuzumab for relapsed or refractory indolent non-Hodgkin’s lymphomas. Therapeutic Advances in Hematology 7:2, pages 85-93.
Crossref
Crossref
Aradhana Awasthi, Janet Ayello, Carmella Van de Ven, Mona Elmacken, Anthony Sabulski, Matthew J. Barth, Myron S. Czuczman, Humayun Islam, Christian Klein & Mitchell S. Cairo. (2015) Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. British Journal of Haematology 171:5, pages 763-775.
Crossref
Crossref
Tim Illidge, Christian Klein, Laurie H. Sehn, Andrew Davies, Gilles Salles & Guillaume Cartron. (2015) Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treatment Reviews 41:9, pages 784-792.
Crossref
Crossref
Carolyn J. Owen & Douglas A. Stewart. (2015) Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Therapeutic Advances in Hematology 6:4, pages 161-170.
Crossref
Crossref
Katelyn T. Byrne, Robert H. Vonderheide, Elizabeth M. Jaffee & Todd D. Armstrong. (2015) Special Conference on Tumor Immunology and Immunotherapy: A New Chapter. Cancer Immunology Research 3:6, pages 590-597.
Crossref
Crossref
Hua Ren, Chengwei Zhang, Liwei Su, Xin Bi, Chao Wang, Liang Wang & Bo Wu. (2015) Type II anti-CD20 mAb-induced lysosome mediated cell death is mediated through a ceramide-dependent pathway. Biochemical and Biophysical Research Communications 457:4, pages 572-577.
Crossref
Crossref
Valentin Goede, Christian Klein & Stephan Stilgenbauer. (2015) Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncology Research and Treatment 38:4, pages 185-192.
Crossref
Crossref
Agnieszka Karczmarczyk & Krzysztof Giannopoulos. (2015) Obinutuzumab jako nowa szansa terapeutyczna dla chorych na przewlekłą białaczkę limfocytową. Acta Haematologica Polonica 46:1, pages 35-41.
Crossref
Crossref
Christian Klein, Marina Bacac, Pablo Umaña & Michael Wenger. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1695
1732
.